Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Graeme J. Moffat
Comment on “Using Human ‘Experiments of Nature’ to Predict Drug Safety Issues: An Example With PCSK9 Inhibitors”
Drug Safety
Toxicology
Pharmacology
Related publications
Reply to Ward and Colleagues’ Comment on “Using Human Experiments of Nature to Predict Drug Safety Issues: An Example With PCSK9 Inhibitors”
Drug Safety
Toxicology
Pharmacology
Mice With Human Ectopic Artificial Livers (HEALs) to Predict Human Drug Metabolism and Drug-Drug Interactions
Science-Business eXchange
PCSK9 Peptide Inhibitors
Science-Business eXchange
Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice
Postgraduate Medicine
Medicine
Prm124 - Modelling Likely Cardiovascular Disease Mortality With Pcsk9 Inhibitors Using a Synthetic Population
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Are PCSK9 Inhibitors Cost Effective?
PharmacoEconomics
Health Policy
Public Health
Occupational Health
Pharmacology
Environmental
PCSK9 Inhibitors: When Statins Aren't Enough
Prescriber
Pharmacology
Hurdles With Using in Vitro Models to Predict Human Blood-Brain Barrier Drug Permeability: A Special Focus on Transporters and Metabolizing Enzymes
Current Drug Metabolism
Clinical Biochemistry
Pharmacology
Correction To: Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents With ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug–Drug Interactions With Moderate CYP3A4 Inhibitors or Inducers
Paediatric Drugs
Child Health
Pediatrics
Perinatology
Pharmacology
